HGB

EQS-News: W&W Group continues to improve its market position in 2023

Retrieved on: 
Mittwoch, April 10, 2024

The W&W Group has continued to make good progress on customer proximity, market relevance and cost efficiency.

Key Points: 
  • The W&W Group has continued to make good progress on customer proximity, market relevance and cost efficiency.
  • In the 2023 financial year, the Wüstenrot & Württembergische Group (W&W) saw good, in some cases excellent development of new business in nearly all lines.
  • Wüstenrot Bausparkasse AG, which set another new record, and the Württembergische property and life insurance business achieved growth well above the market average.
  • The W&W Group expects consolidated net income to increase in the current 2024 financial year, while adverse external influences persist.

EQS-News: Epigenomics AG publishes financial results for fiscal year 2023

Retrieved on: 
Mittwoch, April 10, 2024

Berlin (Germany), March 14, 2024 – Epigenomics AG (FSE: ECX, the “Company”) today reported financial results (according to HGB) for fiscal year 2023.

Key Points: 
  • Berlin (Germany), March 14, 2024 – Epigenomics AG (FSE: ECX, the “Company”) today reported financial results (according to HGB) for fiscal year 2023.
  • In July 2023, Epigenomics AG entered into an agreement with New Day Diagnostics LLC for the sale of substantially all of its assets, which was approved by the Extraordinary General Meeting in September 2023 and closed in October 2023.
  • Based on the measures taken, Epigenomics AG expects that the available financial resources will be sufficient until 2026.
  • The annual financial statements for the 2023 fiscal year can be found on the Epigenomics website at: https://www.epigenomics.com/news-investors/financial-reports/ .

EQS-News: IBU-tec advanced materials AG publishes key financial figures 2023 / 2024 significant growth in sales and EBITDA again expected

Retrieved on: 
Mittwoch, April 10, 2024

EUR 3.0 million

Key Points: 
  • EUR 3.0 million
    Important milestones achieved in the battery sector at the beginning of 2024: Cooperation with LANXESS and launch of the new product IBUvolt® LFP 402
    Weimar, March 21, 2024 – IBU-tec advanced materials AG ("IBU-tec", ISIN: DE000A0XYHT5) publishes its audited key financial figures for the 2023 financial year in accordance with HGB accounting.
  • Accordingly, revenue in the most recently expected range was EUR 48.2 million, compared to EUR 53.9 million in the 2022 financial year (see ad hoc announcement dated December 21, 2023).
  • EBITDA amounted to around EUR 3.0 million, compared to EUR 6.7 million in the same period of the previous year.
  • Accordingly, the EBITDA margin is expected to be around 7% in the 2024 financial year.

EQS-News: CHAPTERS Group AG finishes successful 2023 financial year; Strong momentum continues in 2024

Retrieved on: 
Mittwoch, März 13, 2024

CHAPTERS Group AG finishes successful 2023 financial year; Strong momentum continues in 2024

Key Points: 
  • CHAPTERS Group AG finishes successful 2023 financial year; Strong momentum continues in 2024
    The issuer is solely responsible for the content of this announcement.
  • 2023 was a transformative year for CHAPTERS Group AG as the group made significant progress on several strategic initiatives in building the home for mission-critical businesses in Europe.
  • In addition, CHAPTERS Group AG added several key hires to bolster the team at CHAPTERS Group AG for further growth.
  • In addition, CHAPTERS Group AG increased its ownership in Fintiba GmbH from 39.9% to 55% and spun-off the property services group of NGC Nachfolgekapital.

EQS-News: publity AG with expected negative annual result 2023 due to non-cash value adjustments

Retrieved on: 
Mittwoch, März 13, 2024

March 2024 – publity AG ("publity", ISIN DE0006972508) announces its audited annual figures for 2023 according to HGB accounting and reports a net loss for the year of EUR -236.8 million (FY 2022: EUR -192.5 million).

Key Points: 
  • March 2024 – publity AG ("publity", ISIN DE0006972508) announces its audited annual figures for 2023 according to HGB accounting and reports a net loss for the year of EUR -236.8 million (FY 2022: EUR -192.5 million).
  • This is mainly due to extensive non-cash value adjustments as part of the restructuring of the subsidiary PREOS Global Office Real Estate & Technology AG (see ad hoc disclosure dated November 15, 2023).
  • As of December 31, 2023, total assets amounted to EUR 254.4 million with a correspondingly robust equity ratio of 53.1 %.
  • The 2023 annual financial statements are available at the following link: https://www.publity.org/en/investor-relations-en/#financial-calendar-fin...
    publity invites you to the Annual General Meeting on April 11, 2024.

EQS-News: NEON EQUITY AG with leap in profits in 2023

Retrieved on: 
Donnerstag, Februar 15, 2024

Frankfurt am Main, 15 February 2024 – NEON EQUITY AG (NEON EQUITY ISIN: DE000A3DW408), a founder-led investor and growth enabler, announces its preliminary, unaudited key financial figures for 2023 according to HGB accounting and was able to significantly increase its profit.

Key Points: 
  • Frankfurt am Main, 15 February 2024 – NEON EQUITY AG (NEON EQUITY ISIN: DE000A3DW408), a founder-led investor and growth enabler, announces its preliminary, unaudited key financial figures for 2023 according to HGB accounting and was able to significantly increase its profit.
  • NEON EQUITY was thus able to continue its profitable growth in the 2023 financial year.
  • NEON EQUITY has also supported numerous companies in their growth financing, for example the international nuclear fusion company ALPHA RING.
  • Thomas Olek, CEO and founder of NEON EQUITY: "2023 was a very important year for us.

Kamau Therapeutics Emerges from Stealth With Clinical-Stage Novel Gene Correction Technology Targeting Life-Threatening Genetic Diseases

Retrieved on: 
Donnerstag, Dezember 7, 2023

Kamau Therapeutics ("Kamau" or "the Company"), a clinical-stage gene correction company, announced today its emergence from stealth, following a strategic transaction with Graphite Bio (“Graphite”).

Key Points: 
  • Kamau Therapeutics ("Kamau" or "the Company"), a clinical-stage gene correction company, announced today its emergence from stealth, following a strategic transaction with Graphite Bio (“Graphite”).
  • The newly established company will retain control of all intellectual property (IP) related to HDR-based CRISPR gene correction as well as the IND application.
  • Kamau's HDR gene correction technology holds immense promise in enhancing human health outcomes through curative cell therapies.
  • Through this collaboration, Kamau is actively initiating technology transfer and is focused on elevating the HDR technology, increasing cell yield, and improving overall cell health.

EQS-News: Ludwig Beck am Rathauseck-Textilhaus Feldmeier AG: Slight increase in sales compared to previous year in the third quarter of 2023

Retrieved on: 
Donnerstag, Oktober 26, 2023

Despite of the adverse conditions in the third quarter, LUDWIG BECK at least kept the previous year's level and ended the quarter on par with 2022.

Key Points: 
  • Despite of the adverse conditions in the third quarter, LUDWIG BECK at least kept the previous year's level and ended the quarter on par with 2022.
  • In online retail, LUDWIG BECK further increased its sales compared to the previous year.
  • LUDWIG BECK generated gross sales of € 59.6m in the first nine months of the fiscal year 2023 (previous year: € 56.4m).
  • In the third quarter, LUDWIG BECK achieved gross sales of € 22.6m at group level (previous year: € 22.4m).

EQS-News: NEON EQUITY AG with successful 1st half-year 2023 / EBT at 5.79 million Euro

Retrieved on: 
Freitag, September 29, 2023

Frankfurt am Main, September 29, 2023 – NEON EQUITY AG (NEON EQUITY ISIN: DE000A3DW408), a founder-managed investor and growth enabler, presents key financial figures for the 1st half of the year, which was characterized by clearly positive results and dynamic strategic expansion.

Key Points: 
  • Frankfurt am Main, September 29, 2023 – NEON EQUITY AG (NEON EQUITY ISIN: DE000A3DW408), a founder-managed investor and growth enabler, presents key financial figures for the 1st half of the year, which was characterized by clearly positive results and dynamic strategic expansion.
  • EBIT in H1 was €1.66 million and earnings before taxes, EBT, was €5.79 million.
  • In addition, NEON EQUITY plans to open offices in Abu Dhabi, London, Miami and Singapore by the end of 2023 / early 2024.
  • Thomas Olek, CEO and founder of NEON EQUITY: "The good key figures for the first half of 2023 prove that NEON EQUITY is on a growth course and active in future markets.

EQS-News: publity AG's figures for the first half of 2023 put it on course to break even for the year as a whole

Retrieved on: 
Freitag, September 29, 2023

In 2022, publity had reported a significant loss of EUR -195 million.

Key Points: 
  • In 2022, publity had reported a significant loss of EUR -195 million.
  • In the first half of 2023, there was only a slightly negative result of EUR -1.5 million (previous year: EUR 5.2 million).
  • Revenues amounted to EUR 2.0 million in the first half of the year, down from EUR 10.0 million in the first half of 2022.
  • In the first half of the year, publity continued to push its ESG strategy and established itself on the market as a green asset manager.